Vessel analysis programs underrate carotid disease

Article

Semiautomated vessel analysis software tends to underestimate the degree of carotid stenosis, particularly at levels that require corrective action, according to a study presented at the 2006 RSNA meeting.

Semiautomated vessel analysis software tends to underestimate the degree of carotid stenosis, particularly at levels that require corrective action, according to a study presented at the 2006 RSNA meeting.

Dr. William Boonn and colleagues analyzed data from 12 patients undergoing carotid angiography using multislice CT and six commercially available vessel analysis systems. They found underestimation of stenosis greater than 70% that ranged from 12% to 50%. The estimates worsened as degree of stenosis increased. However, they also found these vessel analysis systems provide improved visualization and other benefits. Study results suggest that vendors must improve the consistency and accuracy of automated stenosis measurements, Boonn said.

Boonn, an imaging informatics fellow at VA Maryland Health Care System when the study was conducted, currently works at the University of Pennsylvania.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.